Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
复制标题
开发免疫细胞因子 IL-2-183B2scFv，用于卵巢癌的靶向免疫治疗。
DOI：
10.1016/j.ygyno.2006.05.016
复制
发表时间：
2006
影响因子：
4.7
通讯作者：
Chen,Xiaoxin
中科院分区：
文献类型：
--
作者：
Zhang,Xinyan;Feng,Jie;Ye,Xue;Yao,Yu;Zhou,Ping;Chen,Xiaoxin
OBJECTIVESThe purpose of this study was to develop an immunocytokine for immunotherapy of human ovarian cancer.METHODSThe single-chain Fv of a monoclonal antibody, COC183B2, specific for an ovarian carcinoma-associated antigen (OC183B2), was genetically fused with the coding sequence of interleukin 2 (IL-2). The fusion protein, also called immunocytokine, IL-2-183B2scFv, was expressed in CHO cells and examined for its specificity and biological function.RESULTSThe immunocytokine, IL-2-183B2scFv, retained the functions of both the antibody and IL-2. It was able to target IL-2 to tumor cells that overexpress OC183B2, and stimulate the proliferation of an IL-2-dependent cell line, CTLL-2.CONCLUSIONSThe IL-2-183B2scFv maintains the functions of both IL-2 and antibody. It can be potentially used for immunotherapy of ovarian cancer by delivering a high concentration of IL-2 to OC183B2-expressing ovarian cancer cells.
